Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT

NCT03689894 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Insufficient accrual

Conditions

Chronic Graft-versus-host-disease

Interventions

DRUG: Ibrutinib
DRUG: Rituximab

Sponsor

Dartmouth-Hitchcock Medical Center